Adaptimmune stock plunges after announcing Nasdaq delisting plans
PARSIPPANY, N.J. - Health Canada has approved Lenivia (izenivetmab injection), a long-acting monoclonal antibody therapy developed by Zoetis Inc. (NYSE: ZTS) for alleviating pain associated with osteoarthritis in dogs, according to a company press release. The approval comes as Zoetis maintains its position as a leading animal health company with robust financials, including a 71.5% gross profit margin and an overall "Good" financial health rating according to InvestingPro analysis.
Lenivia provides pain relief for three months with a single injection by targeting nerve growth factor (NGF), a mediator of pain and inflammation. The therapy demonstrated increased mobility and decreased pain in dogs after one injection during a nine-month field study.
Osteoarthritis affects nearly 40 percent of dogs of any age or size, causing joint inflammation, pain and mobility issues. While the disease cannot be cured, treatments aim to alleviate pain and improve quality of life.
"Health Canada’s approval of Lenivia makes it the world’s first monoclonal antibody to alleviate OA pain in dogs for three months," said Rob Polzer, Executive Vice President and President of Research and Development at Zoetis.
Lenivia joins Librela (bedinvetmab injection) in Zoetis’ portfolio of canine osteoarthritis pain products. Both target NGF, but Lenivia is designed to work for a longer period by binding to a different site on NGF.
The medication is administered subcutaneously once every three months and should not be used in dogs with known hypersensitivity to izenivetmab, breeding dogs, pregnant or lactating dogs, or dogs less than 12 months of age.
Reported side effects include balance problems, weakness, decreased appetite, vomiting, diarrhea, and increased thirst and urination.
Zoetis, a Fortune 500 company, generated revenue of $9.3 billion in 2024 and employs approximately 13,800 people worldwide. Currently trading near its 52-week low, InvestingPro analysis suggests the stock is undervalued, with 12 additional exclusive ProTips available to subscribers. The company has maintained consistent dividend payments for 13 consecutive years, with a recent dividend yield of 1.39%. For detailed insights and comprehensive analysis, investors can access the full Pro Research Report, available exclusively on InvestingPro, covering this and 1,400+ other top US stocks.
In other recent news, Zoetis Inc. announced that its canine osteoarthritis pain treatment, Lenivia, received a positive opinion from the European Medicines Agency’s Committee for Veterinary Medicinal Products, recommending marketing authorization in the European Union. The European Commission is expected to make a final decision by the fourth quarter of 2025. Additionally, Zoetis declared a $0.50 per share dividend for the fourth quarter of 2025, with payment scheduled for December 2, 2025.
Zoetis also received conditional FDA approval for its Dectomax-CA1 Injectable, a parasite control product for preventing and treating New World screwworm infestations in cattle. This marks the first approved drug in the U.S. for such infestations, offering protection for up to 21 days. Furthermore, the European Medicines Agency’s Committee for Veterinary Medicinal Products has recommended marketing authorization for Portela, a new treatment for cats with osteoarthritis pain. If approved, Portela would be the first long-acting anti-nerve growth factor monoclonal antibody therapy for cats, providing three months of pain relief with a single injection.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.